Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
Orexo AB (STO: ORX) (OTCQX: ORXOY) has announced its participation in Pareto Securities' 15th Annual Healthcare Conference on September 19, 2024, at Downtown Camper by Scandic in Stockholm, Sweden. The company's SVP and Head of R&D, Robert Rönn, will deliver a company presentation from 2:25-2:45 CET in the Event Small room.
Additionally, Robert Rönn and Lena Wange, Investor Relations, will be available for one-on-one meetings during the conference. This event provides an opportunity for Orexo to showcase its developments and engage with investors and industry professionals in the healthcare sector.
Orexo AB (STO: ORX) (OTCQX: ORXOY) ha annunciato la propria partecipazione alla 15ª Conferenza Annuale sulla Salute di Pareto Securities il 19 settembre 2024, presso il Downtown Camper by Scandic a Stoccolma, Svezia. Il VP e Capo R&D dell'azienda, Robert Rönn, presenterà l'azienda dalle 14:25 alle 14:45 CET nella Sala Event Small.
Inoltre, Robert Rönn e Lena Wange, Relazioni con gli Investitori, saranno disponibili per incontri individuali durante la conferenza. Questo evento offre a Orexo l'opportunità di mostrare i propri sviluppi e interagire con investitori e professionisti del settore sanitario.
Orexo AB (STO: ORX) (OTCQX: ORXOY) ha anunciado su participación en la 15ª Conferencia Anual de Salud de Pareto Securities el 19 de septiembre de 2024, en el Downtown Camper by Scandic en Estocolmo, Suecia. El vicepresidente y jefe de I+D de la empresa, Robert Rönn, presentará la compañía de 14:25 a 14:45 CET en la Sala Pequeña del Evento.
Además, Robert Rönn y Lena Wange, Relaciones con Inversores, estarán disponibles para reuniones uno a uno durante la conferencia. Este evento proporciona a Orexo una oportunidad para mostrar sus desarrollos y interactuar con inversores y profesionales de la industria de la salud.
오렉소 AB (STO: ORX) (OTCQX: ORXOY)는 파레토 증권 제15회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 19일 스웨덴 스톡홀름의 스칸딕 다운타운 캠퍼에서 열릴 예정입니다. 회사의 수석 부사장이자 R&D 책임자인 로버트 뢰른이 이벤트 스몰 룸에서 CET 기준으로 14:25에서 14:45까지 회사 발표를 진행합니다.
추가로, 로버트 뢰른과 레나 완게, 투자 관계 담당자가 컨퍼런스 동안 일대일 회의를 위해 참석할 예정입니다. 이 이벤트는 오렉소가 자사의 개발을 소개하고 헬스케어 분야의 투자자 및 업계 전문가와 소통할 수 있는 기회를 제공합니다.
Orexo AB (STO: ORX) (OTCQX: ORXOY) a annoncé sa participation à la 15e Conférence Annuelle sur la Santé de Pareto Securities qui se tiendra le 19 septembre 2024 au Downtown Camper by Scandic à Stockholm, Suède. Le SVP et responsable R&D de l'entreprise, Robert Rönn, fera une présentation de l'entreprise de 14h25 à 14h45 CET dans la salle Event Small.
De plus, Robert Rönn et Lena Wange, Relations Investisseurs, seront disponibles pour des réunions individuelles pendant la conférence. Cet événement offre à Orexo l'opportunité de présenter ses développements et d'échanger avec des investisseurs et des professionnels de l'industrie de la santé.
Orexo AB (STO: ORX) (OTCQX: ORXOY) hat seine Teilnahme an der 15. Jahreskonferenz für Gesundheitswesen von Pareto Securities am 19. September 2024 im Downtown Camper by Scandic in Stockholm, Schweden, bekannt gegeben. Der SVP und Leiter F&E des Unternehmens, Robert Rönn, wird von 14:25 bis 14:45 CET in dem Raum Event Small eine Unternehmenspräsentation halten.
Zusätzlich werden Robert Rönn und Lena Wange, Investor Relations, während der Konferenz für persönliche Gespräche zur Verfügung stehen. Diese Veranstaltung bietet Orexo die Möglichkeit, seine Entwicklungen zu präsentieren und mit Investoren und Fachleuten aus dem Gesundheitssektor in Kontakt zu treten.
- None.
- None.
UPPSALA,
On the day, between 2:25-2:45 CET (room Event Small), Robert Rönn, SVP and Head of R&D, will give a company presentation. Robert Rönn and Lena Wange, Investor Relations, will also be available for 1-1 meetings.
For more information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
+46 18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to
About AmorphOX®
Orexo's world-class drug delivery technology, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.
For more information about the company please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 9 am CET on September 3, 2024.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
4032221_0.png | |
4032221_1.png |
View original content:https://www.prnewswire.com/news-releases/orexo-to-participate-in-pareto-securities-15th-annual-healthcare-conference-2024-302236482.html
SOURCE Orexo
FAQ
When and where is Orexo (ORXOY) presenting at the Pareto Securities Healthcare Conference?
Who will be representing Orexo (ORXOY) at the Pareto Securities Healthcare Conference?
What is the significance of Orexo's (ORXOY) participation in the Pareto Securities Healthcare Conference?
How can investors contact Orexo (ORXOY) for more information about their conference participation?
